Tag
OTCMKTS: RHHBY
- Faeth Therapeutics signs Roche supply deal for breast cancer trial
- Climb Bio reports 38% immunologic remission in kidney trial
- DiaMedica Therapeutics reaches 200 patients in pivotal stroke trial
- TG Therapeutics reports seven-year BRIUMVI disability and safety findings
- Waters Corporation and Quest Diagnostics plan nationwide home HPV screening
- ANI Pharmaceuticals reports Phase 4 eye‑implant trial met both endpoints
- Roche reports vamikibart vision gains through week 52 in two trials
- Roche Holding AG gains FDA approval for Tecentriq in stage III dMMR colon cancer
- Genmab A/S reports 51% lower progression or death risk in Phase 3 lymphoma trial
- Novo Nordisk A/S says FDA extends denecimig review over facility remediation
- Surrozen gains FDA IND clearance for SZN‑8141 macular edema trial
- DBV Technologies submits peanut patch BLA for children aged 4 to 7
- Merck says remigromig met BRUNELLO vision endpoint, flags eye risks
- Ionis Pharmaceuticals' Phase 3 kidney trial meets proteinuria endpoint
- Early detection breakthrough means pancreatic cancer could be diagnosed in minutes
- TG Therapeutics stock spikes on strong financials and optimism for its flagship drug
- Poseida Therapeutics shares skyrocket on acquisition from pharma-giant Roche